PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Clinical trial NCT04644406 · UNKNOWN
Trial details
- NCT number
- NCT04644406
- Sponsor
- Hospices Civils de Lyon
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2020-12-01
- Primary completion
- 2022-12-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.